Literature DB >> 27578137

Type 1 hyperlipoproteinemia in a child with large homozygous deletion encompassing GPIHBP1.

Nivedita Patni1, Julie Brothers2, Chao Xing3, Abhimanyu Garg4.   

Abstract

Type I hyperlipoproteinemia (T1HLP) usually presents with extreme hypertriglyceridemia, recurrent episodes of acute pancreatitis, lipemia retinalis, and cutaneous eruptive xanthomas. We report a unique 10-year-old male of Indian origin who presented in neonatal period with transient obstructive jaundice and xanthomas in the pancreas and kidneys. Serum triglycerides stabilized with extremely low-fat diet although he subsequently developed pancreatic atrophy. Extreme hypertriglyceridemia failed to respond to treatment with fenofibrate, fish oil, and orlistat. Whole-exome sequencing of the parents and patient was performed. Copy number variation analysis revealed a large deletion in chromosome 8 containing the entire GPIHBP1, which was confirmed by Sanger sequencing to be 54,623 bp deletion. Review of the literature revealed a slightly higher maximum triglyceride levels in those with homozygous null vs missense mutations suggesting severe disease in those with nonfunctional vs dysfunctional GPIHBP1 protein. Visceral xanthomas and pancreatic atrophy can be part of the spectrum of clinical features in patients with T1HLP. We highlight the need to perform copy number variations analysis of whole-exome sequencing data for finding disease-causing variants. There is also an urgent need to develop novel targeted therapies for patients with T1HLP. Published by Elsevier Inc.

Entities:  

Keywords:  Chylomicronemia; GPIHBP1; Type 1 hyperlipoproteinemia; Whole-exome sequencing; Xanthomas

Mesh:

Substances:

Year:  2016        PMID: 27578137     DOI: 10.1016/j.jacl.2016.04.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  6 in total

1.  GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia.

Authors:  Xuchen Hu; Geesje M Dallinga-Thie; G Kees Hovingh; Sandy Y Chang; Norma P Sandoval; Tiffany Ly P Dang; Isamu Fukamachi; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Loren G Fong; Michael Ploug; Stephen G Young; Anne P Beigneux
Journal:  J Clin Lipidol       Date:  2017-06-13       Impact factor: 4.766

2.  Mutating a conserved cysteine in GPIHBP1 reduces amounts of GPIHBP1 in capillaries and abolishes LPL binding.

Authors:  Christopher M Allan; Cris J Jung; Mikael Larsson; Patrick J Heizer; Yiping Tu; Norma P Sandoval; Tiffany Ly P Dang; Rachel S Jung; Anne P Beigneux; Pieter J de Jong; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

3.  Partial LPL deletions: rare copy-number variants contributing towards severe hypertriglyceridemia.

Authors:  Jacqueline S Dron; Jian Wang; Adam D McIntyre; Henian Cao; John F Robinson; P Barton Duell; Priya Manjoo; James Feng; Irina Movsesyan; Mary J Malloy; Clive R Pullinger; John P Kane; Robert A Hegele
Journal:  J Lipid Res       Date:  2019-09-13       Impact factor: 5.922

4.  A 1-month-old infant with chylomicronemia due to GPIHBP1 gene mutation treated by plasmapheresis.

Authors:  Mo Kyung Jung; Juhyun Jin; Hyun Ok Kim; Ahreum Kwon; Hyun Wook Chae; Seok Jin Kang; Duk Hee Kim; Ho-Seong Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2017-03-31

5.  A homozygous variant in the GPIHBP1 gene in a child with severe hypertriglyceridemia and a systematic literature review.

Authors:  Ursa Sustar; Urh Groselj; Sabeen Abid Khan; Saeed Shafi; Iqbal Khan; Jernej Kovac; Barbara Jenko Bizjan; Tadej Battelino; Fouzia Sadiq
Journal:  Front Genet       Date:  2022-08-16       Impact factor: 4.772

Review 6.  Current Diagnosis and Management of Primary Chylomicronemia.

Authors:  Hiroaki Okazaki; Takanari Gotoda; Masatsune Ogura; Shun Ishibashi; Kyoko Inagaki; Hiroyuki Daida; Toshio Hayashi; Mika Hori; Daisaku Masuda; Kota Matsuki; Shinji Yokoyama; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-13       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.